DBV Technologies (NASDAQ:DBVT) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of DBV Technologies (NASDAQ:DBVT) in a research report report published on Wednesday. The brokerage issued a hold rating on the stock.

DBVT has been the subject of several other reports. JMP Securities restated a “market outperform” rating and issued a $10.00 price objective on shares of DBV Technologies in a report on Tuesday, December 10th. HC Wainwright upped their price target on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Price Performance

Shares of DBVT opened at $3.09 on Wednesday. DBV Technologies has a 1 year low of $2.20 and a 1 year high of $9.90. The company has a 50 day simple moving average of $3.36 and a two-hundred day simple moving average of $3.87. The firm has a market cap of $63.56 million, a P/E ratio of -0.69 and a beta of 0.64.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.